Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Miralles Gines Diego, holds the title of President & Head of R&D at Artiva Biotherapeutics, Inc..
On 2026-11-17, the insider transacted 1,043 shares.The shares were transacted at a weighted average price of $3.91 per share, resulting in a total market-relevant value of $4K.
Miralles Gines Diego (President & Head of R&D) sold $4K of $ARTV
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.